The Anthem Biosciences IPO closed today, July 16, 2025, and witnessed a subscription of 3.66 times on Day 3 so far. The IPO, which opened on July 14, 2025, aimed to raise ₹3,395 crore through an entirely offer-for-sale (OFS) of 5,95,61,404 equity shares. The price band for the IPO was set at ₹540 to ₹570 per equity share.
Subscription Status
By the end of Day 2, the IPO had been subscribed 3.48 times. The category-wise subscription details were as follows:
Final subscription data for Day 3 is awaited.
Grey Market Premium (GMP)
The grey market premium (GMP) for Anthem Biosciences IPO has been trending upward. On July 16, 2025, the GMP stood at ₹156, suggesting a likely listing price of around ₹726, a potential listing gain of 27.37%. However, it's important to note that GMP is volatile and should not be the sole basis for investment decisions.
Financial Performance
Anthem Biosciences has demonstrated strong financial performance in recent years:
For the year ended March 2025, the company reported revenues of ₹1,844.55 crores and a PAT of ₹451 crores. The net margins were a healthy 23.4%, and the EPS was ₹8.04.
Company Overview
Anthem Biosciences is a contract research development and manufacturing organization (CRDMO) with fully integrated operations spanning across drug discovery, development, and manufacturing. The company offers services across the drug life cycle, with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities. As of September 30, 2024, Anthem was actively involved in 196 projects, including discovery, early-phase, late-phase, and commercial manufacturing for 10 molecules. The company serves a broad customer base across 44 countries and holds multiple patents in India and overseas.
IPO Details
Recommendations and Reviews
Several brokerage houses have recommended subscribing to the Anthem Biosciences IPO, citing the company's position in a high-growth segment and its strong financial track record. One analyst noted that the promoter founder would continue to hold over 52% of the company and is not selling a single share in the OFS issue, which is a comforting factor for investors. Another source mentions that the issue is fairly priced and that the company has the potential to continue to grow its revenue and profitability ratios compared to its peers.
Should you apply?
The decision to apply for the IPO depends on individual investment objectives and risk appetite. Here are some factors to consider:
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Please consult with a qualified financial advisor before making any investment decisions.
